Analyst Ratings For Clearside Biomedical (NASDAQ:CLSD)
Today, Wedbush reiterated its Outperform rating on Clearside Biomedical (NASDAQ:CLSD) with a price target of $29.00.
Some recent analyst ratings include
- 3/20/2018-Wedbush Reiterated Rating of Outperform.
- 3/6/2018-JPMorgan Chase & Co. Reiterated Rating of Overweight .
- 3/5/2018-JMP Securities Reiterated Rating of Outperform.
- 10/25/2017-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For Clearside Biomedical (NASDAQ:CLSD)
Clearside Biomedical (NASDAQ:CLSD) has insider ownership of 20.90% and institutional ownership of 38.66%.
- On 12/7/2017 Clay Thorp, Director, sold 5,000 with an average share price of $6.13 per share and the total transaction amounting to $30,650.00.
- On 12/5/2017 Clay Thorp, Director, sold 15,000 with an average share price of $6.37 per share and the total transaction amounting to $95,550.00.
- On 11/16/2017 Clay Thorp, Director, sold 35,000 with an average share price of $7.00 per share and the total transaction amounting to $245,000.00.
- On 11/14/2017 Clay Thorp, Director, sold 15,000 with an average share price of $7.02 per share and the total transaction amounting to $105,300.00.
- On 10/19/2017 Daniel H White, Insider, sold 8,000 with an average share price of $7.82 per share and the total transaction amounting to $62,560.00.
- On 10/5/2017 Clay Thorp, Director, sold 35,000 with an average share price of $8.57 per share and the total transaction amounting to $299,950.00.
- On 9/15/2017 Clay Thorp, Director, sold 24,500 with an average share price of $7.52 per share and the total transaction amounting to $184,240.00.
Recent Trading Activity for Clearside Biomedical (NASDAQ:CLSD)
Shares of Clearside Biomedical closed the previous trading session at 11.98 up +0.03 0.25% with 11.90999984741211 shares trading hands.